Genotyping of Stathmin and Its Association with Clinical Factors and Survival in Patients with Ovarian Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2013 Apr 20

PMID 23599786

Citations 3

Authors

Lisha Ying

Dan Su

Jianqing Zhu

Shenglin Ma

Dionyssios Katsaros

Herbert Yu

Affiliations

Soon will be listed here.

Abstract

Stathmin is closely correlated with the progression and prognosis of a number of types of human cancer. The present study analyzed the associations between genetic variations in the stathmin gene and clinical outcomes of ovarian cancer. A total of 178 patients with epithelial ovarian cancer were treated with cytoreductive surgery followed by platinum-based chemotherapy. DNA was extracted from fresh tumor samples obtained during surgery. A total of 32 DNA samples were selected randomly for resequencing of the stathmin gene. Tag single nucleotide polymorphisms (SNPs) were identified based on the haplotype model as analyzed by PolyPhred software. Direct sequencing was employed in the genotyping of stathmin in 178 cases. A total of 10 nucleotide variations in stathmin were identified, of which 3 high-frequency variations were known SNPs from databases and 7 were new variations with low frequencies. The tag SNPs rs159531 and rs11376635 were selected from the linkage disequilibrium block of the gene to genotype stathmin in 178 cases. The distribution of the rs159531 genotype in ovarian cancer was 52.8% C/C, 35.4% C/T and 11.2% T/T. The distribution of the rs11376635 genotype in ovarian cancer was 32.0% G/G, 48.3% G/-, 18.5% -/-. The main haplotypes calculated by phase2.0 software were 55.6% CG, 27.8% T-, 15.4% C- and 1.2% TG. However, no associations between the stathmin genotype or haplotype and the outcomes in patients with ovarian cancer were observed. The stathmin genotype and haplotype were not associated with the phenotype of patients with ovarian cancer.

Citing Articles

Overexpression of Stathmin 1 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation and Migration in Ovarian Cancer.

Nie L, Zhang C, Song H, Zhao Q, Cheng L, Zhang P Dis Markers. 2022; 2022:3554100.

PMID: 35186166 PMC: 8849943. DOI: 10.1155/2022/3554100.

Stathmin 1 expression predicts prognosis and benefits from adjuvant chemotherapy in patients with gallbladder carcinoma.

Bo X, Wang J, Fu Q, Wang Y, Liu H, Xu J Oncotarget. 2018; 8(65):108548-108555.

PMID: 29312550 PMC: 5752463. DOI: 10.18632/oncotarget.19625.

Ophiobolin A Induces Autophagy and Activates the Mitochondrial Pathway of Apoptosis in Human Melanoma Cells.

Rodolfo C, Rocco M, Cattaneo L, Tartaglia M, Sassi M, Aducci P PLoS One. 2016; 11(12):e0167672.

PMID: 27936075 PMC: 5147944. DOI: 10.1371/journal.pone.0167672.

References

Aravantinos G, Fountzilas G, Kosmidis P, Dimopoulos M, Stathopoulos G, Pavlidis N . Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol. 2005; 16(7):1116-22. DOI: 10.1093/annonc/mdi223. View

Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View

Trovik J, Wik E, Stefansson I, Marcickiewicz J, Tingulstad S, Staff A . Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res. 2011; 17(10):3368-77. DOI: 10.1158/1078-0432.CCR-10-2412. View

Canzonieri V, Barzan L, Franchin G, Vaccher E, Talamini R, Sulfaro S . Alteration of G1/S transition regulators influences recurrences in head and neck squamous carcinomas. J Cell Physiol. 2011; 227(1):233-8. DOI: 10.1002/jcp.22723. View

Pagani F, Baralle F . Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004; 5(5):389-96. DOI: 10.1038/nrg1327. View

Lippert T, Ruoff H, Volm M . Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung. 2008; 58(6):261-4. DOI: 10.1055/s-0031-1296504. View

Sun G, Yan J, Noltner K, Feng J, Li H, Sarkis D . SNPs in human miRNA genes affect biogenesis and function. RNA. 2009; 15(9):1640-51. PMC: 2743066. DOI: 10.1261/rna.1560209. View

Yamada K, Matsuzaki S, Hattori T, Kuwahara R, Taniguchi M, Hashimoto H . Increased stathmin1 expression in the dentate gyrus of mice causes abnormal axonal arborizations. PLoS One. 2010; 5(1):e8596. PMC: 2797614. DOI: 10.1371/journal.pone.0008596. View

Jourdain I, Lachkar S, Charbaut E, Gigant B, Knossow M, Sobel A . A synergistic relationship between three regions of stathmin family proteins is required for the formation of a stable complex with tubulin. Biochem J. 2003; 378(Pt 3):877-88. PMC: 1224029. DOI: 10.1042/BJ20031413. View

10.

Scully R, Sobin L . Histologic typing of ovarian tumors. Arch Pathol Lab Med. 1987; 111(9):794-5. View

11.

Brocke B, Lesch K, Armbruster D, Moser D, Muller A, Strobel A . Stathmin, a gene regulating neural plasticity, affects fear and anxiety processing in humans. Am J Med Genet B Neuropsychiatr Genet. 2009; 153B(1):243-51. DOI: 10.1002/ajmg.b.30989. View

12.

Shepherd J . Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989; 96(8):889-92. DOI: 10.1111/j.1471-0528.1989.tb03341.x. View

13.

Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P . Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology. 2007; 46(3):759-68. DOI: 10.1002/hep.21736. View

14.

Alli E, Yang J, Hait W . Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene. 2006; 26(7):1003-12. DOI: 10.1038/sj.onc.1209864. View

15.

Ehlis A, Bauernschmitt K, Dresler T, Hahn T, Herrmann M, Roser C . Influence of a genetic variant of the neuronal growth associated protein Stathmin 1 on cognitive and affective control processes: an event-related potential study. Am J Med Genet B Neuropsychiatr Genet. 2011; 156B(3):291-302. DOI: 10.1002/ajmg.b.31161. View

16.

Zheng P, Liu Y, Chen L, Liu X, Xiao Z, Zhao L . Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res. 2010; 9(10):4897-905. DOI: 10.1021/pr100712t. View

17.

Saunders M, Liang H, Li W . Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci U S A. 2007; 104(9):3300-5. PMC: 1805605. DOI: 10.1073/pnas.0611347104. View

18.

Jourdain L, Curmi P, Sobel A, Pantaloni D, Carlier M . Stathmin: a tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry. 1997; 36(36):10817-21. DOI: 10.1021/bi971491b. View

19.

Yuan R, Jeng Y, Chen H, Lai P, Pan H, Hsieh F . Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006; 209(4):549-58. DOI: 10.1002/path.2011. View

20.

Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L . Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate. 2007; 67(10):1038-52. DOI: 10.1002/pros.20601. View